Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Archetype Analysis Identifies Distinct Profiles in Renal Transplant Recipients with Transplant Glomerulopathy Associated with Allograft Survival.

Aubert O, Higgins S, Bouatou Y, Yoo D, Raynaud M, Viglietti D, Rabant M, Hidalgo L, Glotz D, Legendre C, Delahousse M, Shah N, Sis B, Campbell P, Mengel M, Jouven X, Van Huyen JD, Lefaucheur C, Loupy A.

J Am Soc Nephrol. 2019 Apr;30(4):625-639. doi: 10.1681/ASN.2018070777. Epub 2019 Mar 14.

PMID:
30872323
2.

Response to treatment and long-term outcomes in kidney transplant recipients with acute T cell-mediated rejection.

Bouatou Y, Viglietti D, Pievani D, Louis K, Duong Van Huyen JP, Rabant M, Aubert O, Taupin JL, Glotz D, Legendre C, Loupy A, Lefaucheur C.

Am J Transplant. 2019 Feb 12. doi: 10.1111/ajt.15299. [Epub ahead of print]

PMID:
30748089
3.

Correction: Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis.

Bouquegneau A, Loheac C, Aubert O, Bouatou Y, Viglietti D, Empana JP, Ulloa C, Murad MH, Legendre C, Glotz D, Jackson AM, Zeevi A, Schaub S, Taupin JL, Reed EF, Friedewald JJ, Tyan DB, Süsal C, Shapiro R, Woodle ES, Hidalgo LG, O'Leary J, Montgomery RA, Kobashigawa J, Jouven X, Jabre P, Lefaucheur C, Loupy A.

PLoS Med. 2018 Jul 27;15(7):e1002637. doi: 10.1371/journal.pmed.1002637. eCollection 2018 Jul.

4.

Assessment of climate change effects on mountain ecosystems through a cross-site analysis in the Alps and Apennines.

Rogora M, Frate L, Carranza ML, Freppaz M, Stanisci A, Bertani I, Bottarin R, Brambilla A, Canullo R, Carbognani M, Cerrato C, Chelli S, Cremonese E, Cutini M, Di Musciano M, Erschbamer B, Godone D, Iocchi M, Isabellon M, Magnani A, Mazzola L, Morra di Cella U, Pauli H, Petey M, Petriccione B, Porro F, Psenner R, Rossetti G, Scotti A, Sommaruga R, Tappeiner U, Theurillat JP, Tomaselli M, Viglietti D, Viterbi R, Vittoz P, Winkler M, Matteucci G.

Sci Total Environ. 2018 May 15;624:1429-1442. doi: 10.1016/j.scitotenv.2017.12.155. Epub 2017 Dec 27.

PMID:
29929254
5.

Complement-binding anti-HLA antibodies are independent predictors of response to treatment in kidney recipients with antibody-mediated rejection.

Viglietti D, Bouatou Y, Kheav VD, Aubert O, Suberbielle-Boissel C, Glotz D, Legendre C, Taupin JL, Zeevi A, Loupy A, Lefaucheur C.

Kidney Int. 2018 Oct;94(4):773-787. doi: 10.1016/j.kint.2018.03.015. Epub 2018 May 22.

PMID:
29801667
6.

Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis.

Bouquegneau A, Loheac C, Aubert O, Bouatou Y, Viglietti D, Empana JP, Ulloa C, Murad MH, Legendre C, Glotz D, Jackson AM, Zeevi A, Schaub S, Taupin JL, Reed EF, Friedewald JJ, Tyan DB, Süsal C, Shapiro R, Woodle ES, Hidalgo LG, O'Leary J, Montgomery RA, Kobashigawa J, Jouven X, Jabre P, Lefaucheur C, Loupy A.

PLoS Med. 2018 May 25;15(5):e1002572. doi: 10.1371/journal.pmed.1002572. eCollection 2018 May. Erratum in: PLoS Med. 2018 Jul 27;15(7):e1002637.

7.

Recognition of i-IF/TA as a component of the T cell-mediated rejection spectrum: Unselected population approach vs random case selection.

Lefaucheur C, Viglietti D, Loupy A.

Am J Transplant. 2018 Mar;18(3):771-772. doi: 10.1111/ajt.14667. Epub 2018 Jan 30. No abstract available.

8.

Dynamic Prognostic Score to Predict Kidney Allograft Survival in Patients with Antibody-Mediated Rejection.

Viglietti D, Loupy A, Aubert O, Bestard O, Duong Van Huyen JP, Taupin JL, Glotz D, Legendre C, Jouven X, Delahousse M, Kamar N, Lefaucheur C.

J Am Soc Nephrol. 2018 Feb;29(2):606-619. doi: 10.1681/ASN.2017070749. Epub 2017 Dec 18.

9.

Biomarkers of IgA vasculitis nephritis in children.

Pillebout E, Jamin A, Ayari H, Housset P, Pierre M, Sauvaget V, Viglietti D, Deschenes G, Monteiro RC, Berthelot L; HSPrognosis group.

PLoS One. 2017 Nov 30;12(11):e0188718. doi: 10.1371/journal.pone.0188718. eCollection 2017.

10.

Value of biomarkers for predicting immunoglobulin A vasculitis nephritis outcome in an adult prospective cohort.

Berthelot L, Jamin A, Viglietti D, Chemouny JM, Ayari H, Pierre M, Housset P, Sauvaget V, Hurtado-Nedelec M, Vrtovsnik F, Daugas E; HSPrognosis Group, Monteiro RC, Pillebout E; members of the HSPrognosis Group .

Nephrol Dial Transplant. 2018 Sep 1;33(9):1579-1590. doi: 10.1093/ndt/gfx300.

PMID:
29126311
11.

T cell-mediated rejection is a major determinant of inflammation in scarred areas in kidney allografts.

Lefaucheur C, Gosset C, Rabant M, Viglietti D, Verine J, Aubert O, Louis K, Glotz D, Legendre C, Duong Van Huyen JP, Loupy A.

Am J Transplant. 2018 Feb;18(2):377-390. doi: 10.1111/ajt.14565. Epub 2017 Nov 21.

12.

Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment.

Lefaucheur C, Viglietti D, Hidalgo LG, Ratner LE, Bagnasco SM, Batal I, Aubert O, Orandi BJ, Oppenheimer F, Bestard O, Rigotti P, Reisaeter AV, Kamar N, Lebranchu Y, Duong Van Huyen JP, Bruneval P, Glotz D, Legendre C, Empana JP, Jouven X, Segev DL, Montgomery RA, Zeevi A, Halloran PF, Loupy A.

J Am Soc Nephrol. 2018 Feb;29(2):620-635. doi: 10.1681/ASN.2017050589. Epub 2017 Oct 17.

13.

Plasma cell neoplasia after kidney transplantation: French cohort series and review of the literature.

Kormann R, François H, Moles T, Dantal J, Kamar N, Moreau K, Bachelet T, Heng AE, Garstka A, Colosio C, Ducloux D, Sayegh J, Savenkoff B, Viglietti D, Sberro R, Rondeau E, Peltier J.

PLoS One. 2017 Jun 21;12(6):e0179406. doi: 10.1371/journal.pone.0179406. eCollection 2017. Review.

14.

Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis.

Gosset C, Viglietti D, Rabant M, Vérine J, Aubert O, Glotz D, Legendre C, Taupin JL, Duong Van-Huyen JP, Loupy A, Lefaucheur C.

Kidney Int. 2017 Sep;92(3):729-742. doi: 10.1016/j.kint.2017.03.033. Epub 2017 May 26.

PMID:
28554738
15.

Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients.

Aubert O, Loupy A, Hidalgo L, Duong van Huyen JP, Higgins S, Viglietti D, Jouven X, Glotz D, Legendre C, Lefaucheur C, Halloran PF.

J Am Soc Nephrol. 2017 Jun;28(6):1912-1923. doi: 10.1681/ASN.2016070797. Epub 2017 Mar 2.

16.

From Humoral Theory to Performant Risk Stratification in Kidney Transplantation.

Lefaucheur C, Viglietti D, Mangiola M, Loupy A, Zeevi A.

J Immunol Res. 2017;2017:5201098. doi: 10.1155/2017/5201098. Epub 2017 Jan 2. Review.

17.

Value of Donor-Specific Anti-HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss.

Viglietti D, Loupy A, Vernerey D, Bentlejewski C, Gosset C, Aubert O, Duong van Huyen JP, Jouven X, Legendre C, Glotz D, Zeevi A, Lefaucheur C.

J Am Soc Nephrol. 2017 Feb;28(2):702-715. doi: 10.1681/ASN.2016030368. Epub 2016 Aug 4.

18.

Evidence for an important role of both complement-binding and noncomplement-binding donor-specific antibodies in renal transplantation.

Viglietti D, Lefaucheur C, Glotz D.

Curr Opin Organ Transplant. 2016 Aug;21(4):433-40. doi: 10.1097/MOT.0000000000000324. Review.

PMID:
27348472
19.

Therapeutic Hypothermia in Deceased Organ Donors and Kidney-Graft Function.

Viglietti D, Gosset C, Lefaucheur C.

N Engl J Med. 2015 Dec 31;373(27):2686-7. doi: 10.1056/NEJMc1511744. No abstract available.

PMID:
26716924
20.

C1 Inhibitor in Acute Antibody-Mediated Rejection Nonresponsive to Conventional Therapy in Kidney Transplant Recipients: A Pilot Study.

Viglietti D, Gosset C, Loupy A, Deville L, Verine J, Zeevi A, Glotz D, Lefaucheur C.

Am J Transplant. 2016 May;16(5):1596-603. doi: 10.1111/ajt.13663. Epub 2016 Mar 3.

21.

IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury.

Lefaucheur C, Viglietti D, Bentlejewski C, Duong van Huyen JP, Vernerey D, Aubert O, Verine J, Jouven X, Legendre C, Glotz D, Loupy A, Zeevi A.

J Am Soc Nephrol. 2016 Jan;27(1):293-304. doi: 10.1681/ASN.2014111120. Epub 2015 Aug 20.

22.

Long term outcomes of transplantation using kidneys from expanded criteria donors: prospective, population based cohort study.

Aubert O, Kamar N, Vernerey D, Viglietti D, Martinez F, Duong-Van-Huyen JP, Eladari D, Empana JP, Rabant M, Verine J, Rostaing L, Congy N, Guilbeau-Frugier C, Mourad G, Garrigue V, Morelon E, Giral M, Kessler M, Ladrière M, Delahousse M, Glotz D, Legendre C, Jouven X, Lefaucheur C, Loupy A.

BMJ. 2015 Jul 31;351:h3557. doi: 10.1136/bmj.h3557.

23.

Determinants and Outcomes of Accelerated Arteriosclerosis: Major Impact of Circulating Antibodies.

Loupy A, Vernerey D, Viglietti D, Aubert O, Duong Van Huyen JP, Empana JP, Bruneval P, Glotz D, Legendre C, Jouven X, Lefaucheur C.

Circ Res. 2015 Aug 14;117(5):470-82. doi: 10.1161/CIRCRESAHA.117.306340. Epub 2015 Jun 8.

PMID:
26056252
24.

Complement inhibition in HLA-incompatible kidney transplants: persisting antibody-mediated injury despite marked decrease of clinical ABMR.

Loupy A, Viglietti D, Mengel M.

Am J Transplant. 2015 May;15(5):1139-40. doi: 10.1111/ajt.13172. Epub 2015 Mar 2. No abstract available.

25.

Kidney allograft fibrosis after transplantation from uncontrolled circulatory death donors.

Viglietti D, Abboud I, Hill G, Vernerey D, Nochy D, Antoine C, Fieux F, Assayag M, Verine J, Gaudez F, Loupy A, Glotz D, Lefaucheur C.

Transplantation. 2015 Feb;99(2):409-15. doi: 10.1097/TP.0000000000000228.

PMID:
25222117
26.

Acute enteritis associated with Coxsackievirus A19 in a kidney transplant patient.

Melica G, Langlois AL, Le Goff J, Viglietti D, Glotz D, Molina JM, Peraldi MN.

Transpl Infect Dis. 2014 Apr;16(2):344-6. doi: 10.1111/tid.12191. Epub 2014 Mar 17.

PMID:
24628788
27.

Fully automated quantification of cytomegalovirus (CMV) in whole blood with the new sensitive Abbott RealTime CMV assay in the era of the CMV international standard.

Schnepf N, Scieux C, Resche-Riggon M, Feghoul L, Xhaard A, Gallien S, Molina JM, Socié G, Viglietti D, Simon F, Mazeron MC, Legoff J.

J Clin Microbiol. 2013 Jul;51(7):2096-102. doi: 10.1128/JCM.00067-13. Epub 2013 Apr 24.

28.

Kidney graft dysfunction in simultaneous pancreas-kidney recipients after pancreas failure: analysis of early and late protocol biopsies.

Viglietti D, Serrato T, Abboud I, Antoine C, Pillebout E, Busson M, Desgrandchamps F, Meria P, Godin M, Hurault de Ligny B, Thervet E, Legendre C, Suberbielle C, Verine J, Glotz D, Peraldi MN.

Clin Transplant. 2013 May-Jun;27(3):E249-55. doi: 10.1111/ctr.12095. Epub 2013 Feb 13.

PMID:
23406495
29.

How many times can parvovirus B19-related anemia recur in solid organ transplant recipients?

Gosset C, Viglietti D, Hue K, Antoine C, Glotz D, Pillebout E.

Transpl Infect Dis. 2012 Oct;14(5):E64-70. doi: 10.1111/j.1399-3062.2012.00773.x. Epub 2012 Aug 30. Review.

PMID:
22931551
30.

Preliminary results of transplantation with kidneys donated after cardiocirculatory determination of death: a French single-centre experience.

Abboud I, Viglietti D, Antoine C, Gaudez F, Meria P, Tariel E, Mongiat-Artus P, Desgranchamps F, Roussin F, Fieux F, Jacob L, Randoux C, Michel C, Flamant M, Lefaucheur C, Pillebout E, Serrato T, Peraldi MN, Glotz D.

Nephrol Dial Transplant. 2012 Jun;27(6):2583-7. doi: 10.1093/ndt/gfr709. Epub 2011 Dec 20.

PMID:
22187319
31.

Perirenal fluid collections and monoclonal gammopathy.

Viglietti D, Sverzut JM, Peraldi MN.

Nephrol Dial Transplant. 2012 Jan;27(1):448-9. doi: 10.1093/ndt/gfr433. Epub 2011 Aug 2.

PMID:
21810768
32.

Pulsatile perfusion preservation for expanded-criteria donors kidneys: Impact on delayed graft function rate.

Abboud I, Antoine C, Gaudez F, Fieux F, Lefaucheur C, Pillebout E, Viglietti D, Serrato T, Vérine J, Flamant M, Peraldi MN, Glotz D.

Int J Artif Organs. 2011 Jun;34(6):513-8. doi: 10.5301/IJAO.2011.8458.

PMID:
21725933
33.

[Cytopenias following kidney transplantation].

Viglietti D, Peraldi MN.

Nephrol Ther. 2011 Nov;7(6):474-8. doi: 10.1016/j.nephro.2011.04.002. Epub 2011 May 18. Review. French.

PMID:
21596639
34.

Chronic interstitial nephritis in an HIV type-1-infected patient receiving ritonavir-boosted atazanavir.

Viglietti D, Verine J, De Castro N, Scemla A, Daudon M, Glotz D, Pillebout E.

Antivir Ther. 2011;16(1):119-21. doi: 10.3851/IMP1700.

PMID:
21311116
35.

The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.

Durelli L, Barbero P, Bergui M, Versino E, Bassano MA, Verdun E, Ferrero B, Rivoiro C, Ferrero C, Picco E, Ripellino P, Viglietti D, Giuliani G, Montanari E, Clerico M; OPTIMS Study Group.

J Neurol. 2008 Sep;255(9):1315-23. doi: 10.1007/s00415-008-0879-6. Epub 2008 Sep 25.

PMID:
18825438
36.

The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews.

Clerico M, Rivoiro C, Contessa G, Viglietti D, Durelli L.

Clin Neurol Neurosurg. 2008 Nov;110(9):878-85. doi: 10.1016/j.clineuro.2007.10.020. Epub 2008 Mar 4. Review.

PMID:
18164542

Supplemental Content

Loading ...
Support Center